Pon1 (paraoxonase 1) - Rat Genome Database

Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap)  (beta) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer) Overgo Probe Designer
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Gene: Pon1 (paraoxonase 1) Rattus norvegicus
Analyze
Symbol: Pon1
Name: paraoxonase 1
RGD ID: 620062
Description: Enables aryldialkylphosphatase activity. Involved in several processes, including response to fatty acid; response to fluoride; and response to lipopolysaccharide. Located in extracellular space and intracellular membrane-bounded organelle. Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); cerebrovascular disease (multiple); eye disease (multiple); glucose metabolism disease (multiple); and hematologic cancer (multiple). Orthologous to human PON1 (paraoxonase 1); PARTICIPATES IN clopidogrel pharmacodynamics pathway; clopidogrel pharmacokinetics pathway; organophosphate response pathway; INTERACTS WITH (+)-schisandrin B; 17beta-estradiol; 2,2',4,4',5,5'-hexachlorobiphenyl.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: A-esterase 1; aromatic esterase 1; PON 1; serum aryldialkylphosphatase 1; serum paraoxonase/arylesterase 1
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Allele / Splice: Pon1em1Mcwi   Pon1em2Mcwi   Pon1em3Mcwi   Pon1em1Lizh  
Genetic Models: SS-Pon1em2Mcwi SS-Pon1em1Mcwi SS-Pon1em3Mcwi SD-Pon1em1Lizh
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.2433,294,737 - 33,325,759 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl433,294,722 - 33,321,360 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx438,253,781 - 38,280,327 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.0434,179,920 - 34,206,462 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.0432,589,698 - 32,616,248 (-)NCBIRnor_WKY
Rnor_6.0430,249,749 - 30,276,297 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl430,249,742 - 30,276,372 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0430,156,712 - 30,183,204 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4429,936,314 - 29,964,821 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1429,975,057 - 30,003,299 (-)NCBI
Celera428,821,674 - 28,848,125 (-)NCBICelera
Cytogenetic Map4q13NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
Acute Coronary Syndrome  (ISO)
acute lymphoblastic leukemia  (ISO)
Agricultural Workers' Diseases  (ISO)
Albuminuria  (ISO)
allergic rhinitis  (ISO)
Alzheimer's disease  (ISO)
amyotrophic lateral sclerosis  (ISO)
amyotrophic lateral sclerosis type 1  (ISO)
anemia  (ISO)
arteriosclerosis  (ISO)
Arteritis  (ISO)
atherosclerosis  (ISO)
autistic disorder  (ISO)
Behcet's disease  (ISO)
beta thalassemia  (ISO)
beta-thalassemia major  (ISO)
Birth Weight  (ISO)
bone disease  (ISO)
Brain Neoplasms  (ISO)
breast cancer  (ISO)
capillary leak syndrome  (ISO)
cardiovascular system disease  (ISO)
cataract  (ISO)
celiac disease  (ISO)
cerebral cavernous malformation  (ISO)
cerebral infarction  (ISO)
Chemical and Drug Induced Liver Injury  (ISO)
cholestasis  (ISO)
chronic lymphocytic leukemia  (ISO)
chronic obstructive pulmonary disease  (ISO)
Colorectal Neoplasms  (ISO)
congestive heart failure  (ISO)
Constipation  (ISO)
coronary artery disease  (ISO)
coronary artery vasospasm  (ISO)
Coronary Disease  (ISO)
Crohn's disease  (ISO)
dementia  (ISO)
Diabetes Complications  (ISO)
diabetes mellitus  (ISO)
diabetic angiopathy  (ISO)
Diabetic Nephropathies  (ISO)
diabetic retinopathy  (ISO)
disease of metabolism  (ISO)
exfoliation syndrome  (ISO)
Experimental Diabetes Mellitus  (ISO)
fatty liver disease  (ISO)
glucose intolerance  (ISO)
heart disease  (ISO)
Hematologic Neoplasms  (ISO)
hemorrhoid  (ISO)
Henoch-Schoenlein purpura  (ISO)
hepatocellular carcinoma  (ISO)
Hypercholesterolemia  (ISO)
hyperglycemia  (ISO)
hyperhomocysteinemia  (ISO)
Hyperlipoproteinemia Type II  (ISO)
Hyperlipoproteinemias  (IDA,ISO)
hyperthyroidism  (ISO)
Insulin Resistance  (ISO)
iron deficiency anemia  (ISO)
keratoconus  (ISO)
Kuhnt-Junius degeneration  (ISO)
Lung Neoplasms  (ISO)
lymphoma  (ISO)
macular degeneration  (ISO)
male infertility  (ISO)
membranoproliferative glomerulonephritis  (ISO)
mental depression  (ISO)
Metabolic Syndrome  (ISO)
Micronuclei, Chromosome-Defective  (ISO)
multiple myeloma  (ISO)
myocardial infarction  (ISO)
Nasal Polyps  (ISO)
non-Hodgkin lymphoma  (ISO)
Occupational Diseases  (ISO)
open-angle glaucoma  (ISO)
Organophosphate Poisoning  (ISO)
periodontal disease  (ISO)
persian gulf syndrome  (ISO)
pleomorphic xanthoastrocytoma  (ISO)
Prenatal Exposure Delayed Effects  (ISO)
primary open angle glaucoma  (ISO)
Primitive Neuroectodermal Tumors  (ISO)
prostate cancer  (ISO)
Prostatic Neoplasms  (ISO)
proteinuria  (ISO)
retinal vein occlusion  (ISO)
rheumatoid arthritis  (ISO)
secondary Parkinson disease  (ISO)
sickle cell anemia  (ISO)
Sjogren's syndrome  (ISO)
spina bifida  (ISO)
Spinal Cord Injuries  (IDA)
toxic encephalopathy  (ISO)
type 1 diabetes mellitus  (ISO)
type 2 diabetes mellitus  (ISO)
ulcerative colitis  (ISO)
vitamin B12 deficiency  (ISO)
Yin Deficiency  (IEP)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-schisandrin B  (EXP)
(R)-mevalonic acid  (ISO)
(S)-naringenin  (ISO)
(S)-nicotine  (ISO)
1,2-dilauroyl-sn-glycero-3-phosphocholine(1+)  (ISO)
1-naphthyl isothiocyanate  (ISO)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (EXP,ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (EXP,ISO)
2,2',5,5'-tetrachlorobiphenyl  (EXP)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4,6-tribromophenol  (ISO)
2,4-dinitrotoluene  (EXP)
2,6-di-tert-butyl-4-methylphenol  (ISO)
2-trans,6-trans,10-trans-geranylgeranyl diphosphate  (ISO)
2-trans,6-trans-farnesyl diphosphate  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (EXP,ISO)
3,4-dihydrocoumarin  (ISO)
3,4-methylenedioxymethamphetamine  (EXP)
3-methylcholanthrene  (EXP,ISO)
3H-1,2-dithiole-3-thione  (EXP)
4,4'-sulfonyldiphenol  (ISO)
4-hydroxy-TEMPO  (EXP)
4-hydroxynon-2-enal  (ISO)
4-hydroxyphenyl retinamide  (ISO)
4-nitrophenol  (ISO)
4-nitrophenyl acetate  (ISO)
6-propyl-2-thiouracil  (EXP)
7,9-dihydro-1H-purine-2,6,8(3H)-trione  (ISO)
7-ketocholesterol  (ISO)
acetamide  (EXP)
acetylsalicylic acid  (EXP,ISO)
acrolein  (ISO)
aflatoxin B1  (ISO)
albuterol  (ISO)
aldicarb  (EXP,ISO)
alendronic acid  (EXP)
ammonium chloride  (EXP)
ampicillin  (ISO)
angelica lactone  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
arachidonic acid  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
atazanavir sulfate  (EXP)
atorvastatin calcium  (EXP,ISO)
benzo[a]pyrene  (ISO)
Benzo[k]fluoranthene  (ISO)
bexarotene  (EXP)
bifenthrin  (ISO)
bisphenol A  (EXP,ISO)
bosentan  (ISO)
cadmium atom  (EXP,ISO)
calcium atom  (EXP,ISO)
calcium dichloride  (ISO)
calcium(0)  (EXP,ISO)
carbamazepine  (ISO)
carbon nanotube  (ISO)
chenodeoxycholic acid  (ISO)
chlorpyrifos  (EXP,ISO)
cholesterol  (EXP,ISO)
cholic acid  (EXP,ISO)
chromium(3+) trichloride  (ISO)
ciprofibrate  (ISO)
ciprofloxacin  (ISO)
cisplatin  (EXP)
clindamycin phosphate  (ISO)
clodronic acid  (EXP)
clofibrate  (EXP)
clofibric acid  (EXP,ISO)
clopidogrel  (ISO)
cobalt atom  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
copper(II) sulfate  (ISO)
coumarins  (ISO)
cyclophosphamide  (EXP)
cyclosporin A  (ISO)
desogestrel  (ISO)
dexamethasone  (ISO)
Diallyl sulfide  (ISO)
diazinon  (EXP,ISO)
diazoxon  (ISO)
dichlorvos  (EXP,ISO)
diclofenac  (ISO)
dieldrin  (EXP)
diiodine  (EXP)
diisopropyl fluorophosphate  (ISO)
dimethylarsinic acid  (ISO)
dioleoyl phosphatidylcholine  (ISO)
dioxygen  (ISO)
dipalmitoyl phosphatidylglycerol  (ISO)
disodium selenite  (ISO)
doramapimod  (EXP)
dorsomorphin  (ISO)
edaravone  (EXP)
elemental selenium  (ISO)
endosulfan  (ISO)
entinostat  (ISO)
erucic acid  (ISO)
ethylene glycol bis(2-aminoethyl)tetraacetic acid  (EXP,ISO)
farnesyl diphosphate  (ISO)
fenitrothion  (EXP)
fenofibrate  (ISO)
flavone  (ISO)
fluticasone  (ISO)
fluvastatin  (EXP)
fumonisin B1  (ISO)
furan  (EXP)
gabapentin  (ISO)
gamma-decalactone  (EXP)
glutathione  (ISO)
graphene oxide  (ISO)
GW 4064  (ISO)
high-density lipoprotein cholesterol  (ISO)
homocysteine  (ISO)
hydrazine  (EXP)
hydrogen peroxide  (ISO)
hypochlorous acid  (ISO)
iron atom  (EXP,ISO)
iron(0)  (EXP,ISO)
iron(2+) sulfate (anhydrous)  (ISO)
isorhamnetin  (ISO)
L-ascorbic acid  (EXP,ISO)
L-methionine  (ISO)
lead diacetate  (EXP)
lead(0)  (ISO)
lead(2+)  (ISO)
levetiracetam  (ISO)
levonorgestrel  (ISO)
linoleic acid  (ISO)
lysophosphatidylglycerol  (ISO)
malaoxon  (ISO)
malonaldehyde  (ISO)
mefenamic acid  (ISO)
mercury atom  (ISO)
mercury(0)  (ISO)
metformin  (ISO)
methapyrilene  (EXP)
methidathion  (ISO)
methimazole  (ISO)
methotrexate  (EXP)
methylglyoxal  (ISO)
mithramycin  (ISO)
montelukast  (ISO)
moxifloxacin  (ISO)
N-acetyl-L-cysteine  (EXP)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosomorpholine  (EXP)
Nandrolone decanoate  (ISO)
naphthalene  (EXP,ISO)
nickel atom  (ISO)
nicotine  (ISO)
nitrofen  (EXP)
O-methyleugenol  (ISO)
ochratoxin A  (EXP)
oleic acid  (ISO)
organophosphorus compound  (ISO)
orlistat  (ISO)
oxamyl  (EXP,ISO)
ozone  (EXP,ISO)
palladium  (ISO)
palmitoleic acid  (ISO)
pamidronate  (EXP)
panobinostat  (ISO)
paracetamol  (EXP,ISO)
paraoxon  (EXP,ISO)
Paraoxon-methyl  (EXP,ISO)
parathion  (ISO)
parathion-methyl  (ISO)
pentane-2,3-dione  (EXP)
perfluorononanoic acid  (ISO)
perfluorooctanoic acid  (EXP,ISO)
permethrin  (EXP)
phenobarbital  (EXP,ISO)
phenyl acetate  (EXP,ISO)
phenylacetic acid  (EXP,ISO)
phenylmercury acetate  (ISO)
phenytoin  (ISO)
pirinixic acid  (ISO)
pitavastatin  (ISO)
pitavastatin(1-)  (ISO)
platinum  (ISO)
platinum(0)  (ISO)
potassium dichromate  (ISO)
pralidoxime  (EXP)
pregnenolone 16alpha-carbonitrile  (ISO)
primidone  (ISO)
proanthocyanidin  (EXP)
propanal  (ISO)
pyrrolidine  (ISO)
quercetin  (EXP,ISO)
quinolin-2(1H)-one  (ISO)
quinolin-2-ol  (ISO)
reactive oxygen species  (ISO)
resveratrol  (ISO)
rifampicin  (ISO)
Risedronate sodium  (EXP)
ritonavir  (EXP)
rutin  (EXP)
salicylates  (ISO)
saquinavir  (EXP)
sarin  (ISO)
SB 431542  (ISO)
selenic acid  (EXP)
selenium atom  (ISO)
silicon dioxide  (ISO)
simvastatin  (ISO)
sodium arsenite  (ISO)
sodium dichromate  (EXP)
sodium fluoride  (EXP)
sodium perchlorate  (EXP)
Soman  (ISO)
squalene  (ISO)
streptozocin  (EXP)
sulfisomidine  (ISO)
sulfisoxazole  (ISO)
tamoxifen  (ISO)
taurocholic acid  (ISO)
tetrachloromethane  (EXP,ISO)
theophylline  (ISO)
thioacetamide  (EXP)
tiotropium bromide  (ISO)
titanium dioxide  (ISO)
trichostatin A  (ISO)
valproic acid  (EXP,ISO)
vancomycin  (EXP)
varenicline  (ISO)
vitamin E  (EXP)
vorinostat  (ISO)
VX nerve agent  (ISO)
zinc atom  (ISO)
zinc(0)  (ISO)
zingerone  (EXP)
zoledronic acid  (EXP)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function

Molecular Pathway Annotations     Click to see Annotation Detail View
Phenotype Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers. Abdin AA, etal., J Diabetes Complications. 2009 Mar 26.
2. Oxidative indices correlate with dyslipidemia and pro-inflammatory cytokine levels in fluoride-exposed rats. Afolabi OK, etal., Arh Hig Rada Toksikol. 2013 Dec;64(4):521-9. doi: 10.2478/10004-1254-64-2013-2351.
3. Lycopene amends LPS induced oxidative stress and hypertriglyceridemia via modulating PCSK-9 expression and Apo-CIII mediated lipoprotein lipase activity. Alvi SS, etal., Biomed Pharmacother. 2017 Dec;96:1082-1093. doi: 10.1016/j.biopha.2017.11.116. Epub 2017 Nov 22.
4. Serum PON1 arylesterase activity in relation to hyperhomocysteinaemia and oxidative stress in young adult central retinal venous occlusion patients. Angayarkanni N, etal., Eye (Lond). 2008 Jul;22(7):969-74. Epub 2007 Dec 14.
5. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Aslan M, etal., Atherosclerosis. 2007 Apr;191(2):397-402. Epub 2006 May 8.
6. Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Ates O, etal., Tohoku J Exp Med. 2009 Jan;217(1):17-22.
7. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. The REGICOR Investigators. Aubo C, etal., Eur Heart J. 2000 Jan;21(1):33-8.
8. Association of lipids, lipoproteins, apolipoproteins and paraoxonase enzyme activity with premature coronary artery disease. Azizi F, etal., Coron Artery Dis. 2002 Feb;13(1):9-16.
9. Paraoxonase 1 knockout rats have impaired T cell development at the CD4/CD8 double-negative to double-positive transition stage. Bai L, etal., Sci Rep. 2018 Sep 27;8(1):14457. doi: 10.1038/s41598-018-32780-w.
10. Association of the M55L and Q192R paraoxonase gene polymorphisms with age-related macular degeneration. Baird PN, etal., Am J Ophthalmol. 2004 Oct;138(4):665-6.
11. LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. Barbieri M, etal., J Clin Endocrinol Metab. 2002 Jan;87(1):222-5.
12. Facilitated replacement of Kupffer cells expressing a paraoxonase-1 transgene is essential for ameliorating atherosclerosis in mice. Bradshaw G, etal., Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11029-34. Epub 2005 Jul 25.
13. [Comparative plasma proteomic analysis of patients with multiple myeloma treated with bortezomib-based regimens]. Cumova J, etal., Klin Onkol. 2012;25(1):17-25.
14. NQO1 rs1800566 (C609T), PON1 rs662 (Q192R), and PON1 rs854560 (L55M) polymorphisms segregate the risk of childhood acute leukemias according to age range distribution. de Aguiar Goncalves BA, etal., Cancer Causes Control. 2012 Nov;23(11):1811-9. doi: 10.1007/s10552-012-0060-5. Epub 2012 Sep 14.
15. Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. Deakin S, etal., J Clin Endocrinol Metab. 2002 Mar;87(3):1268-73.
16. Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. Dowling P, etal., BMC Genomics. 2014 Oct 17;15:904. doi: 10.1186/1471-2164-15-904.
17. Oxidant-antioxidant status in Egyptian children with sickle cell anemia: a single center based study. El-Ghamrawy MK, etal., J Pediatr (Rio J). 2014 May-Jun;90(3):286-92. doi: 10.1016/j.jped.2013.09.005. Epub 2014 Feb 5.
18. Decreased HDL-dependent paraoxonase and arylesterase enzyme activity may indicate a worse prognosis in multiple myeloma. Ellidag HY, etal., Asian Pac J Cancer Prev. 2014;15(22):9847-51.
19. Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Erlich PM, etal., Hum Mol Genet. 2006 Jan 1;15(1):77-85. Epub 2005 Nov 30.
20. Enhanced HDL-cholesterol-associated anti-oxidant PON-1 activity in prostate cancer patients. Eroglu M, etal., Kaohsiung J Med Sci. 2013 Jul;29(7):368-73. doi: 10.1016/j.kjms.2012.11.004. Epub 2013 Jan 16.
21. Association study of detoxification genes in age related macular degeneration. Esfandiary H, etal., Br J Ophthalmol. 2005 Apr;89(4):470-4.
22. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Flekac M, etal., Physiol Res. 2008;57(5):717-26. Epub 2007 Oct 11.
23. Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Gallicchio L, etal., Cancer Detect Prev. 2007;31(2):95-101. Epub 2007 Apr 10.
24. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
25. Relationship between paraoxonase-1 (PON1) activity and lipoprotein (a) levels in Turkish coronary artery disease patients living in the Antalya region. Gocmen YA, etal., Eur J Cardiovasc Prev Rehabil. 2005 Apr;12(2):185-6.
26. Serum paraoxonase, arylesterase activity, and oxidative status in patients with nasal polyp. Hao W, etal., Eur Arch Otorhinolaryngol. 2013 May;270(6):1861-5. doi: 10.1007/s00405-012-2307-x. Epub 2012 Dec 13.
27. Expression and activity of paraoxonase 1 in human cataractous lens tissue. Hashim Z, etal., Free Radic Biol Med. 2009 Apr 15;46(8):1089-95. doi: 10.1016/j.freeradbiomed.2009.01.012. Epub 2009 Jan 23.
28. Paraoxonase 1 gene polymorphisms and dementia in humans. Helbecque N, etal., Neurosci Lett 2004 Mar 18;358(1):41-4.
29. Association between PON 1 polymorphisms, PON activity and diabetes complications. Hofer SE, etal., J Diabetes Complications. 2006 Sep-Oct;20(5):322-8.
30. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Ikeda Y, etal., Metabolism. 1998 May;47(5):598-602.
31. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Imai Y, etal., Atherosclerosis. 2000 Apr;149(2):435-42.
32. Paraoxonase 1 gene polymorphisms influence clinical features of open-angle glaucoma. Inagaki Y, etal., Graefes Arch Clin Exp Ophthalmol. 2006 Aug;244(8):984-90. Epub 2006 Jan 13.
33. Trace elements and oxidative stress in chronic obstructive pulmonary disease. Isik B, etal., Saudi Med J. 2005 Dec;26(12):1882-5.
34. Current understanding of the mechanisms involved in metabolic detoxification of warfare nerve agents. Jokanovic M Toxicol Lett. 2009 Jul 10;188(1):1-10. doi: 10.1016/j.toxlet.2009.03.017. Epub 2009 Mar 31.
35. Serum paraoxonase activity is decreased in the active stage of Behcet's disease. Karakucuk S, etal., Br J Ophthalmol. 2004 Oct;88(10):1256-8.
36. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Kerridge I, etal., Br J Haematol. 2002 Aug;118(2):477-81.
37. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Ko YL, etal., Atherosclerosis. 1998 Dec;141(2):259-64.
38. Paraoxonase and arylesterase activities in children with iron deficiency anemia and vitamin B12 deficiency anemia. Koc A, etal., Pediatr Hematol Oncol. 2012 May;29(4):345-53. doi: 10.3109/08880018.2011.645185.
39. Relationship between the paraoxonase 1 (PON1) M55L and Q192R polymorphisms and lymphohaematopoietic cancers in a Greek agricultural population. Kokouva M, etal., Toxicology. 2013 May 10;307:12-6. doi: 10.1016/j.tox.2012.07.003. Epub 2012 Jul 16.
40. Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes - connection with inflammation. Krzystek-Korpacka M, etal., Clin Biochem. 2008 Jul;41(10-11):804-11. doi: 10.1016/j.clinbiochem.2008.03.012. Epub 2008 Apr 4.
41. Dietary fat modulates serum paraoxonase 1 activity in rats. Kudchodkar BJ, etal., J Nutr 2000 Oct;130(10):2427-33.
42. Paraoxonase-1 and oxidative status in common Mediterranean beta-thalassaemia mutations trait, and their relations to atherosclerosis. Labib HA, etal., J Clin Pathol. 2011 May;64(5):437-42. doi: 10.1136/jcp.2011.090209. Epub 2011 Mar 22.
43. The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. Lawlor DA, etal., BMC Genet. 2004 Jun 23;5:17.
44. Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy. Li C and Gu Q, Nephrology (Carlton). 2009 Aug;14(5):514-20. Epub 2008 Feb 3.
45. Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. Lincz LF, etal., Haematologica. 2004 May;89(5):628-9.
46. Serum Protein KNG1, APOC3, and PON1 as Potential Biomarkers for Yin-Deficiency-Heat Syndrome. Liu C, etal., Evid Based Complement Alternat Med. 2016;2016:5176731. doi: 10.1155/2016/5176731. Epub 2016 Oct 24.
47. The relationships between PON1 activity as well as oxLDL levels and coronary artery lesions in CHD patients with diabetes mellitus or impaired fasting glucose. Lu C, etal., Coron Artery Dis. 2008 Dec;19(8):565-73.
48. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Mackness B, etal., Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1545-50. Epub 2006 Apr 20.
49. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Mackness B, etal., Clin Sci (Lond). 2000 Mar;98(3):355-63.
50. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Marsillach J, etal., Clin Exp Pharmacol Physiol. 2007 Apr;34(4):347-9.
51. Postprandial changes in high density lipoproteins in rats subjected to gavage administration of virgin olive oil. Martinez-Beamonte R, etal., PLoS One. 2013;8(1):e55231. doi: 10.1371/journal.pone.0055231. Epub 2013 Jan 29.
52. Oxidative stress, HDL functionality and effects of intravenous iron administration in women with iron deficiency anemia. Merono T, etal., Clin Nutr. 2016 Feb 13. pii: S0261-5614(16)00059-5. doi: 10.1016/j.clnu.2016.02.003.
53. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
54. Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Murata M, etal., Diabet Med. 2004 Aug;21(8):837-44.
55. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
56. Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Nowak M, etal., Clin Exp Med. 2010 Sep;10(3):185-92. doi: 10.1007/s10238-009-0084-7. Epub 2009 Dec 11.
57. Regulatory regions of the paraoxonase 1 (PON1) gene are associated with neovascular age-related macular degeneration (AMD). Oczos J, etal., Age (Dordr). 2013 Oct;35(5):1651-62. doi: 10.1007/s11357-012-9467-x. Epub 2012 Sep 7.
58. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. Odawara M, etal., J Clin Endocrinol Metab. 1997 Jul;82(7):2257-60.
59. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. Ombres D, etal., Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1611-6.
60. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
61. Protective effect of paraoxonase 1 gene variant L55M in retinal vein occlusion. Ortak H, etal., Mol Vis. 2013;19:486-xxx. Epub 2013 Feb 25.
62. Plasma paraoxonase activity and oxidative stress and their relationship to disease severity in children with allergic rhinitis. Ozkaya E, etal., Am J Rhinol Allergy. 2013 Jan;27(1):13-7. doi: 10.2500/ajra.2013.27.3837.
63. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Paragh G, etal., Curr Med Res Opin. 2004 Aug;20(8):1321-7.
64. Protective effect of paraoxonase 1 gene variant Gln192Arg in age-related macular degeneration. Pauer GJ, etal., Am J Ophthalmol. 2010 Mar;149(3):513-22. doi: 10.1016/j.ajo.2009.09.024. Epub 2009 Dec 30.
65. Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of beta-thalassemia/hemoglobin E patients. Phumala Morales N, etal., Clin Chem Lab Med. 2007;45(7):884-9.
66. SMPDB Annotation Import Pipeline Pipeline to import SMPDB annotations from SMPDB into RGD
67. Paraoxonase 1 status in keratoconus: a preliminary study of activity and polymorphism. Poh R, etal., West Indian Med J. 2012 Sep;61(6):569-73.
68. GOA pipeline RGD automated data pipeline
69. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
70. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
71. GLYOXALASE I A111E, PARAOXONASE 1 Q192R AND L55M POLYMORPHISMS IN ITALIAN PATIENTS WITH SPORADIC CEREBRAL CAVERNOUS MALFORMATIONS: A PILOT STUDY. Rinaldi C, etal., J Biol Regul Homeost Agents. 2015 Apr-Jun;29(2):493-500.
72. Paraoxonases are associated with intestinal inflammatory diseases and intracellularly localized to the endoplasmic reticulum. Rothem L, etal., Free Radic Biol Med. 2007 Sep 1;43(5):730-9. Epub 2007 May 10.
73. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Rozenberg O, etal., Free Radic Biol Med. 2008 Jun 1;44(11):1951-9. Epub 2008 Mar 8.
74. Assessment of early atherosclerotic findings in patients with nasal polyposis. Sagit M, etal., Auris Nasus Larynx. 2013 Oct 19. pii: S0385-8146(13)00182-X. doi: 10.1016/j.anl.2013.07.013.
75. Tobacco smoking modifies association between Gln-Arg192 polymorphism of human paraoxonase gene and risk of myocardial infarction. Sen-Banerjee S, etal., Arterioscler Thromb Vasc Biol. 2000 Sep;20(9):2120-6.
76. Antioxidant paraoxonase 1 activity in the metabolic syndrome. Senti M, etal., J Clin Endocrinol Metab. 2003 Nov;88(11):5422-6.
77. The effects of cranberry juice on serum glucose, apoB, apoA-I, Lp(a), and Paraoxonase-1 activity in type 2 diabetic male patients. Shidfar F, etal., J Res Med Sci. 2012 Apr;17(4):355-60.
78. Association of paraoxonase 1 L55M and Q192R single-nucleotide polymorphisms with age-related macular degeneration. Sogut E, etal., Retina. 2013 Oct;33(9):1836-42. doi: 10.1097/IAE.0b013e318287da59.
79. Decreased human paraoxonase-1 activity in patients with Sjogren's syndrome. Szanto A, etal., Int Immunol. 2010 Jul;22(7):605-9. doi: 10.1093/intimm/dxq045. Epub 2010 May 24.
80. Effects of caloric restriction and gender on rat serum paraoxonase 1 activity. Thomas-Moya E, etal., J Nutr Biochem. 2006 Mar;17(3):197-203. Epub 2005 Sep 13.
81. Q192R and L55M Polymorphisms of Paraoxonase 1 Gene in Chronic Myelogenous Leukemia and Chronic Lymphocytic Leukemia. Tomatir AG, etal., Anticancer Res. 2015 Sep;35(9):4807-12.
82. Effects of prostaglandin E1, melatonin, and oxytetracycline on lipid peroxidation, antioxidant defense system, paraoxonase (PON1) activities, and homocysteine levels in an animal model of spinal cord injury. Topsakal C, etal., Spine (Phila Pa 1976). 2003 Aug 1;28(15):1643-52.
83. Iron-ascorbic acid-induced oxidant stress and its quenching by paraoxonase 1 in HDL and the liver: comparison between humans and rats. Trudel K, etal., J Cell Biochem. 2005 Oct 1;96(2):404-11.
84. Oxidative stress and anti-oxidative defence in patients with age-related macular degeneration. Ugurlu N, etal., Curr Eye Res. 2013 Apr;38(4):497-502. doi: 10.3109/02713683.2013.774023. Epub 2013 Feb 22.
85. Paraoxonase 1 phenotype distribution and activity differs in subjects with newly diagnosed Type 2 diabetes (the CODAM Study). van den Berg SW, etal., Diabet Med. 2008 Feb;25(2):186-93.
86. Association of paraoxonase gene polymorphisms with diabetic nephropathy and retinopathy. Wang J, etal., Mol Med Rep. 2013 Dec;8(6):1845-51. doi: 10.3892/mmr.2013.1710. Epub 2013 Oct 2.
87. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. Wang T, etal., Front Immunol. 2022 May 27;13:843408. doi: 10.3389/fimmu.2022.843408. eCollection 2022.
88. Dietary blueberries attenuate atherosclerosis in apolipoprotein E-deficient mice by upregulating antioxidant enzyme expression. Wu X, etal., J Nutr. 2010 Sep;140(9):1628-32. doi: 10.3945/jn.110.123927. Epub 2010 Jul 21.
89. Genome-wide SNP analysis of the Systemic Capillary Leak Syndrome (Clarkson disease). Xie Z, etal., Rare Dis. 2013 Dec 12;1(1). pii: e27445.
90. The activities of paraoxonase, xanthine oxidase, adenosine deaminase and the level of nitrite in pseudoexfoliation syndrome. Yagci R, etal., Ophthalmic Res. 2009;42(3):155-9. doi: 10.1159/000229306. Epub 2009 Jul 23.
91. No association of paraoxonase genotype or atherosclerosis with cerebral amyloid angiopathy. Yamada M, etal., Stroke. 2002 Apr;33(4):896-900.
92. Effect of paraoxonase 1 gene polymorphisms on clinical course of Henoch-Schonlein purpura. Yilmaz A, etal., J Nephrol. 2009 Nov-Dec;22(6):726-32.
93. Studies on protective effects of human paraoxonases 1 and 3 on atherosclerosis in apolipoprotein E knockout mice. Zhang C, etal., Gene Ther. 2010 May;17(5):626-33. Epub 2010 Feb 25.
94. A maternal high-fat diet represses the expression of antioxidant defense genes and induces the cellular senescence pathway in the liver of male offspring rats. Zhang X, etal., J Nutr. 2011 Jul;141(7):1254-9. doi: 10.3945/jn.111.139576. Epub 2011 May 11.
95. Single nucleotide polymorphisms of metabolic syndrome-related genes in primary open angle glaucoma. Zhou G and Liu B, Int J Ophthalmol. 2010;3(1):36-42. doi: 10.3980/j.issn.2222-3959.2010.01.09. Epub 2010 Mar 18.
96. Serum Paraoxonase Activity and Malondialdehyde Serum Concentrations Remain Unaffected in Response to Hydroxyurea Therapy in beta-Thalassemia Patients. Zohaib M, etal., J Clin Pharmacol. 2016 Jul;56(7):869-74. doi: 10.1002/jcph.675. Epub 2015 Dec 28.
Additional References at PubMed
PMID:7638166   PMID:9032442   PMID:9685159   PMID:10479665   PMID:12477932   PMID:15098021   PMID:15342686   PMID:15721011   PMID:15772423   PMID:16641100   PMID:16682745   PMID:16816326  
PMID:17146679   PMID:17460375   PMID:17464102   PMID:17645625   PMID:18458312   PMID:18719679   PMID:19091700   PMID:19144177   PMID:19887391   PMID:20028357   PMID:22516433   PMID:23376485  
PMID:23533145   PMID:24214524   PMID:27499091   PMID:27642496   PMID:27959408   PMID:30503749   PMID:30946296   PMID:35589918  


Genomics

Comparative Map Data
Pon1
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.2433,294,737 - 33,325,759 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl433,294,722 - 33,321,360 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx438,253,781 - 38,280,327 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.0434,179,920 - 34,206,462 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.0432,589,698 - 32,616,248 (-)NCBIRnor_WKY
Rnor_6.0430,249,749 - 30,276,297 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl430,249,742 - 30,276,372 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0430,156,712 - 30,183,204 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4429,936,314 - 29,964,821 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1429,975,057 - 30,003,299 (-)NCBI
Celera428,821,674 - 28,848,125 (-)NCBICelera
Cytogenetic Map4q13NCBI
PON1
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38795,297,676 - 95,324,532 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl795,297,676 - 95,324,532 (-)EnsemblGRCh38hg38GRCh38
GRCh37794,926,988 - 94,953,844 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36794,764,924 - 94,791,780 (-)NCBINCBI36Build 36hg18NCBI36
Build 34794,571,638 - 94,598,495NCBI
Celera789,626,366 - 89,652,590 (-)NCBICelera
Cytogenetic Map7q21.3NCBI
HuRef789,534,701 - 89,560,922 (-)NCBIHuRef
CHM1_1794,857,684 - 94,883,916 (-)NCBICHM1_1
T2T-CHM13v2.0796,533,832 - 96,560,687 (-)NCBIT2T-CHM13v2.0
CRA_TCAGchr7v2794,256,665 - 94,282,884 (-)NCBI
Pon1
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm3965,168,090 - 5,193,987 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl65,168,090 - 5,193,946 (-)EnsemblGRCm39 Ensembl
GRCm3865,168,090 - 5,193,987 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl65,168,090 - 5,193,946 (-)EnsemblGRCm38mm10GRCm38
MGSCv3765,118,090 - 5,143,946 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv3665,118,105 - 5,143,824 (-)NCBIMGSCv36mm8
Celera65,314,337 - 5,340,485 (-)NCBICelera
Cytogenetic Map6A1NCBI
cM Map61.99NCBI
Pon1
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_00495543211,893,473 - 11,923,339 (-)EnsemblChiLan1.0
ChiLan1.0NW_00495543211,893,473 - 11,923,035 (-)NCBIChiLan1.0ChiLan1.0
PON1
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
PanPan1.17100,841,286 - 100,867,493 (-)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl7100,841,286 - 100,867,493 (-)Ensemblpanpan1.1panPan2
Mhudiblu_PPA_v0787,253,476 - 87,279,650 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PON1
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.11420,565,620 - 20,600,774 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1420,565,641 - 20,642,985 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1420,124,634 - 20,159,679 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01420,388,041 - 20,423,054 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1420,388,051 - 20,422,924 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11420,532,696 - 20,567,711 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01420,267,821 - 20,302,851 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01420,525,175 - 20,560,208 (-)NCBIUU_Cfam_GSD_1.0
Pon1
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_02440511833,883,628 - 33,908,421 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365854,954,869 - 4,979,591 (+)EnsemblSpeTri2.0
SpeTri2.0NW_0049365854,954,871 - 4,979,560 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
PON1
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl974,926,048 - 74,974,723 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1974,943,646 - 74,974,720 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2982,327,318 - 82,339,633 (+)NCBISscrofa10.2Sscrofa10.2susScr3
PON1
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.12153,713,434 - 53,739,658 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl2153,714,012 - 53,739,875 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366604250,595,418 - 50,621,447 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Pon1
(Heterocephalus glaber - naked mole-rat)
Naked Mole-rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046248131,949,614 - 1,979,882 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046248131,953,796 - 1,979,846 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Pon1
4 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:165
Count of miRNA genes:119
Interacting mature miRNAs:126
Transcripts:ENSRNOT00000011823
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
61415Eae11Experimental allergic encephalomyelitis QTL 112.9nervous system integrity trait (VT:0010566)post-insult time to onset of experimental autoimmune encephalomyelitis (CMO:0001422)4139505420Rat
634323Hc2Hypercalciuria QTL 22.15urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)421079645210796Rat
619616Bp79Blood pressure QTL 790.0292arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)4521460278882945Rat
2303168Bp330Blood pressure QTL 3304.250.017arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)45214602146446691Rat
2302371Stl22Serum triglyceride level QTL 225.15blood triglyceride amount (VT:0002644)serum triglyceride level (CMO:0000360)4521829457114705Rat
1358203Stl19Serum triglyceride level QTL 192.80.002blood triglyceride amount (VT:0002644)serum triglyceride level (CMO:0000360)4521829465958103Rat
631642Stl2Serum triglyceride level QTL 23.3blood triglyceride amount (VT:0002644)serum triglyceride level (CMO:0000360)4521917856647776Rat
631209Bw2Body weight QTL24.2retroperitoneal fat pad mass (VT:0010430)retroperitoneal fat pad weight to body weight ratio (CMO:0000635)4994088544463908Rat
1300141Bp178Blood pressure QTL 178arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)41002490139524530Rat
6478724Anxrr35Anxiety related response QTL 350.00449defecation behavior trait (VT:0010462)defecation measurement (CMO:0000997)41008408955084089Rat
6478766Anxrr47Anxiety related response QTL 470.09637locomotor behavior trait (VT:0001392)number of entries into a discrete space in an experimental apparatus (CMO:0000960)41008408955084089Rat
6478769Anxrr48Anxiety related response QTL 480.02514locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)41008408955084089Rat
8694374Bw155Body weight QTL 1553.390.001body lean mass (VT:0010483)lean tissue morphological measurement (CMO:0002184)41008408955084089Rat
9590304Scort17Serum corticosterone level QTL 174.960.001blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)41008408955084089Rat
8552906Pigfal3Plasma insulin-like growth factor 1 level QTL 3blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)41008408955084089Rat
631261Tcas3Tongue tumor susceptibility QTL 36.88tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)41081417091360527Rat
2316958Gluco58Glucose level QTL 5810blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)411320076180699135Rat
2303585Bw86Body weight QTL 864body mass (VT:0001259)body weight (CMO:0000012)41467806559678065Rat
2313401Anxrr27Anxiety related response QTL 27aggression-related behavior trait (VT:0015014)tameness/aggressiveness composite score (CMO:0002136)41793350862933508Rat
70222Eae2Experimental allergic encephalomyelitis QTL 24.3nervous system integrity trait (VT:0010566)experimental autoimmune encephalomyelitis incidence/prevalence measurement (CMO:0001046)42133334339505420Rat
1354665Stl10Serum triglyceride level QTL 103.57blood triglyceride amount (VT:0002644)serum triglyceride level (CMO:0000360)42133334344463908Rat
61412Pia2Pristane induced arthritis QTL 23.9joint integrity trait (VT:0010548)post-insult time to onset of experimental arthritis (CMO:0001450)42133334362278020Rat
8552803Bw144Body weight QTL 14416body mass (VT:0001259)change in body weight to body weight ratio (CMO:0002216)42271068534430484Rat
6909122Insul22Insulin level QTL 224.63blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)42690728575585128Rat
6909128Pancm4Pancreatic morphology QTL 411.35pancreas mass (VT:0010144)pancreas wet weight (CMO:0000626)42690728575585128Rat
8655906Rf60Renal function QTL 603.8blood creatinine amount (VT:0005328)creatinine clearance (CMO:0000765)42949419581006281Rat
12798520Anxrr55Anxiety related response QTL 554.450.01locomotor behavior trait (VT:0001392)number of rearing movements with lid-pushing in an experimental apparatus (CMO:0002715)432583980114627242Rat
11530004Niddm71Non-insulin dependent diabetes mellitus QTL 710.001blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)43258419952754138Rat

Markers in Region
RH127354  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2433,294,874 - 33,295,091 (+)MAPPERmRatBN7.2
Rnor_6.0430,249,879 - 30,250,095NCBIRnor6.0
Rnor_5.0430,156,842 - 30,157,058UniSTSRnor5.0
RGSC_v3.4429,936,444 - 29,936,660UniSTSRGSC3.4
Celera428,821,804 - 28,822,020UniSTS
RH 3.4 Map4218.84UniSTS
Cytogenetic Map4q13UniSTS


Genetic Models
This gene Pon1 is modified in the following models/strains

Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High 20 20 14
Medium 16 15 15 1 3
Low 4 24 10 18 10 6 6 11 7 13 8 6
Below cutoff 1 8 3 2 1 2 2 4 16 11 16 2

Sequence

Nucleotide Sequences
RefSeq Transcripts NM_032077 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_039108462 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
GenBank Nucleotide AC124867 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  BC091403 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  CH473959 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  CO562983 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  CO570909 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ209429 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ209439 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ209482 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ209632 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ209702 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ211027 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ211041 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ218360 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ218888 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ219478 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ219506 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ219654 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ219750 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ219776 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ223824 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  JACYVU010000141 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  U94856 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles

Reference Sequences
RefSeq Acc Id: ENSRNOT00000011823   ⟹   ENSRNOP00000011823
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl433,294,722 - 33,314,707 (-)Ensembl
Rnor_6.0 Ensembl430,249,742 - 30,276,372 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000113709   ⟹   ENSRNOP00000079524
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl433,301,958 - 33,321,360 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000114824   ⟹   ENSRNOP00000090277
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl433,298,944 - 33,321,360 (-)Ensembl
RefSeq Acc Id: NM_032077   ⟹   NP_114466
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2433,294,745 - 33,321,296 (-)NCBI
Rnor_6.0430,249,749 - 30,276,297 (-)NCBI
Rnor_5.0430,156,712 - 30,183,204 (-)NCBI
RGSC_v3.4429,936,314 - 29,964,821 (-)RGD
Celera428,821,674 - 28,848,125 (-)RGD
Sequence:
RefSeq Acc Id: XM_039108462   ⟹   XP_038964390
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2433,294,737 - 33,325,759 (-)NCBI
Reference Sequences
RefSeq Acc Id: NP_114466   ⟸   NM_032077
- Peptide Label: precursor
- UniProtKB: Q5BJN6 (UniProtKB/Swiss-Prot),   P55159 (UniProtKB/Swiss-Prot)
- Sequence:
RefSeq Acc Id: ENSRNOP00000011823   ⟸   ENSRNOT00000011823
RefSeq Acc Id: XP_038964390   ⟸   XM_039108462
- Peptide Label: isoform X1
RefSeq Acc Id: ENSRNOP00000090277   ⟸   ENSRNOT00000114824
RefSeq Acc Id: ENSRNOP00000079524   ⟸   ENSRNOT00000113709
Protein Domains
DUF1725

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P55159-F1-model_v2 AlphaFold P55159 1-355 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13692857
Promoter ID:EPDNEW_R3382
Type:initiation region
Name:Pon1_1
Description:paraoxonase 1
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0430,276,308 - 30,276,368EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:620062 AgrOrtholog
BioCyc Gene G2FUF-45712 BioCyc
Ensembl Genes ENSRNOG00000008902 Ensembl, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000011823.5 UniProtKB/TrEMBL
  ENSRNOP00000079524.1 UniProtKB/TrEMBL
  ENSRNOP00000090277.1 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000011823.7 UniProtKB/TrEMBL
  ENSRNOT00000113709.1 UniProtKB/TrEMBL
  ENSRNOT00000114824.1 UniProtKB/TrEMBL
Gene3D-CATH 2.120.10.30 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
IMAGE_CLONE IMAGE:7324332 IMAGE-MGC_LOAD
InterPro 6-blade_b-propeller_TolB-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Arylesterase UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  DUF1725 UniProtKB/TrEMBL
  Paraoxonase1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:84024 UniProtKB/Swiss-Prot
MGC_CLONE MGC:109526 IMAGE-MGC_LOAD
NCBI Gene 84024 ENTREZGENE
PANTHER PTHR11799:SF16 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam Arylesterase UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  DUF1725 UniProtKB/TrEMBL
PharmGKB PON1 RGD
PhenoGen Pon1 PhenoGen
PRINTS PARAOXONASE UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PARAOXONASE1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0A8I5ZN72_RAT UniProtKB/TrEMBL
  A0A8I6A9R4_RAT UniProtKB/TrEMBL
  A0A8L2Q6A6_RAT UniProtKB/TrEMBL
  P55159 ENTREZGENE, UniProtKB/Swiss-Prot
  Q5BJN6 ENTREZGENE
UniProt Secondary O08682 UniProtKB/Swiss-Prot
  Q5BJN6 UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2004-09-10 Pon1  paraoxonase 1      Symbol and Name status set to approved 1299863 APPROVED
2002-08-07 Pon1  paraoxonase 1      Symbol and Name status set to provisional 70820 PROVISIONAL